Parte del contenido de esta aplicación no está disponible en este momento.
Si esta situación persiste, contáctenos aComentarios y contacto
1. (WO2019043701) CORE-SHELL PARTICLES COMPRISING METAL OXIDE AND LANTHANIDE ELEMENT
Nota: Texto obtenido mediante procedimiento automático de reconocimiento óptico de caracteres.
Solo tiene valor jurídico la versión en formato PDF

WHAT IS CLAIMED IS:

1. A composition comprising at least one particle, said at least one particle having a core comprising metal oxide, and a shell comprising an ion of a lanthanide element, wherein said lanthanide element is linked to a polymer and to an active agent, and wherein a weight ratio of said active agent to said metal oxide is in the range of from 1:2 to 3:2, respectively.

2. The composition of claim 1, wherein said metal oxide is selected from the group consisting of: iron oxide, aluminum oxide, zinc oxide, copper oxide, manganese oxide, and any combination thereof.

3. The composition of claim 2, wherein said iron oxide comprises a maghemite y-Fe203 phase.

4. The composition of any one of claims 1 to 3, wherein said metal oxide is in the form of a nanoparticle.

5. The composition of any one of claims 1 to 4, wherein said lanthanide element is selected from the group consisting of: cerium, lanthanum, praseodymium, neodymium, promethium, samarium, europium, gadolinium, terbium, dysprosium, holmium, erbium, thulium, ytterbium, lutetium, and any combination thereof.

6. The composition of claim 5, wherein said lanthanide element is cerium.

7. The composition of any one of claims 1 to 6, wherein said polymer is selected from the group consisting of: polyethylenimine (PEI), poly-L-lysine, chitosan, poly-L-arginine, dendrimeric polyamidoamine (PAMAM), polyacrylate, polyphosphate, polyethyleneglycol (PEG), and any derivative or combination thereof.

8. The composition of any one of claims 1 to 7, wherein the molecular weight of said polymer is in the range of from 500 Da to 60 KDa.

9. The composition of any one of claims 1 to 8, wherein said active agent is selected from the group consisting of: a therapeutic active agent, a diagnostic active agent, and a combination thereof.

10. The composition of claim 9, wherein said therapeutic active agent is selected from the group consisting of: pentamidine, suramin, melarsoprol, eflornithine, nifurtimox, benznidazole, fexinidazole, oxaborole, pafuramidine, doxorubicin, amphotericin B, a bioactive peptide, a bioactive nucleic acid, and any derivative or combination thereof.

11. The composition of claim 9, wherein said diagnostic active agent is selected from the group consisting of: porphyrin dye, a quinone (e.g., 1,2,4-trihydroxyanthraquinone), folic acid, indocyanine green, a peptide, a nucleic acid, and any derivative or combination thereof.

12. The composition of any one of claims 10 and 11, wherein said peptide comprises one or more residues selected from the group consisting of: Lys, Arg, His, Glu, and Asp, and wherein said peptide is linked to said lanthanide element via the N-terminus of said one or more residues.

13. The composition of any one of claims 10 to 12, wherein said nucleic acid is selected from the group consisting of: siRNA, miRNA, RNAi, dsRNA, DNA, or any combination thereof.

14. The composition of any one of claims 1 to 13, wherein a hydrodynamic diameter of said particle is in the range of from 60 nm to 2 μιη.

15. A pharmaceutical product comprising the composition of any one of claims 1 to 14, and a pharmaceutically acceptable carrier, excipient or adjuvant.

16. The pharmaceutical product according to claim 15, being formulated for systemic or topical administration.

17. The pharmaceutical product according to any one of claims 15 and 16, for use in treating an infectious disease or disorder.

18. The pharmaceutical product according to any one of claims 15 to 17, wherein said disease or disorder is associated with parasitic infection.

19. The pharmaceutical product according to any one of claims 15 to 18, being in the form selected from the group consisting of: paste, cream, lotion, foam, gel, emulsion, ointment, and soap.

20. A method for the treatment of an infectious disease or a disorder in a subject in need thereof, the method comprising administrating to a subject the composition of any one of claims 1 to 14 or the pharmaceutical product of any one of claims 15 to 19, thereby treating said infectious disease or disorder.

21. A method for obtaining a composition comprising at least one particle, having a core comprising metal oxide, and a shell comprising an ion of a lanthanide element, wherein said ion of said lanthanide element has linked thereto a polymer and an active agent, the method comprising the steps of:

a. mixing a solvent, said lanthanide element, and a plurality of particles of said metal oxide, thereby obtaining a suspension, and

b. adding said polymer and the active agent to said suspension.

22. The method of claim 21, wherein the mixing step is performed under ultrasonic agitation.

23. The method of claim 21, wherein said adding said polymer and said active agent is performed simultaneously.